Analysis of elexacaftor + tezacaftor + ivacaftor (&) ivacaftor for cystic fibrosis utilisation, October 2025
Page last updated: 20 March 2026
Drug utilisation sub-committee (DUSC)
October 2025
Abstract
Purpose
To review elexacaftor, tezacaftor and ivacaftor for the treatment of cystic fibrosis as requested by DUSC at its October 2024 meeting.
Date of listing on the Pharmaceutical Benefits Scheme (PBS)
Elexacaftor + tezacaftor + ivacaftor was PBS listed 1 April 2022.
Data Source / methodology
Data extracted from the PBS database maintained by Department of Health, Disability and Ageing, processed by Services Australia were used for the analyses.
Key Findings
- In 2024, there were 3,126 patients supplied 30,208 prescriptions of cystic fibrosis transmembrane conductance regulator (CFTR) modulators, including 307 initiating patients.
- There were 27,089 prescriptions of the combination medicine elexacaftor, tezacaftor and ivacaftor (ELX/TEZ/IVA) supplied to 2,890 patients, including 209 initiating patients.
- Between PBS listing on 1 April 2022 and 30 June 2025, 3,209 patients were supplied ELX/TEZ/IVA, including 1,320 (41%) patients who initiated on and have only been supplied ELX/TEZ/IVA.
- The mean age of patients supplied CFTR modulators in 2024 was 24 years, and the median age was 21 years. The mean age of patients supplied ELX/TEZ/IVA in 2024 was 24 years, and the median age was 21 years.
